FAST BioMedical Successfully Completes Open-Label Proof-of-Concept Study for Measuring Interstitial Volume

FAST BioMedical, a privately held, late-clinical-stage medical technology company, today announces the completion of an open-label study using its technology in chronic dialysis patients.

The goal of the study was to use FAST BioMedical’s technology to determine total volume removal before and after dialysis treatment by measuring both plasma volume and interstitial volume.

Conducted at the Richard L. Roudebush VA Medical Center in Indianapolis, the study evaluated the safety, tolerability and performance of the FAST Technology in chronic dialysis patients with extremely reduced or no kidney function. Based on how FAST BioMedical’s technology works, this was the best initial patient population to establish clinical Proof-of-Concept.

Despite challenges due to the pandemic, the enrollment was successfully completed on time and all study endpoints were met. Specifically, the study demonstrated the company’s second-generation fluorescence instrument works well, clinical Proof-of-Concept in interstitial volume measurement, and the successful implementation of FAST BioMedical’s technology in the clinical workflow for dialysis patients and dialysis units.

“Objectively measuring volume and changes in volume is a critically important unmet need in clinical medicine,” said Arjun D. Sinha, MD, who served as the primary investigator in this study. “FAST BioMedical’s technology performed well in this study, and we look forward to reporting the results in the coming months.”

The clinical samples collected during this study were analyzed at the Indiana Biosciences Research Institute building in the 16 Tech Innovation District. FAST BioMedical has wet lab space in 16 Tech and was able to analyze the collected samples using their second-generation fluorescence instrument in a qualified lab environment.

“Over the course of 2020 and early 2021, the 16 Tech space has allowed us to concentrate on the further refinement of our instruments by providing a proper laboratory environment to validate and test our devices,” said Dan Meier, VP of product development at FAST BioMedical. “The facility itself has given us access to appropriate FDA-compliant resources in one efficient location.”

Although this was a preliminary Proof-of-Concept study for measuring interstitial volume in dialysis patients, the potential impact of measuring interstitial volume in all patients where volume is being managed is profound.  Many clinicians believe measurement of interstitial volume is one of the key critical parameters in these patients.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version